Clinical Trial Update: Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia [NA]

View source ↗

Summary

This clinical trial update reports a terminated study evaluating the FlexAbility Ablation Catheter System by Abbott Medical Devices for reducing monomorphic ven…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ventricular Tachycardia

Drugs mentioned

• FlexAbility Ablation Catheter System

Snippet

Sponsor: Abbott Medical Devices | Conditions: Monomorphic Ventricular Tachycardia | NA | Status: TERMINATED | Results posted: 2018-10-15